

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6607396

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ANTHROGENESIS CORPORATION	02/24/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CELGENE CORPORATION
<b>Street Address:</b>	86 MORRIS AVENUE
<b>City:</b>	SUMMIT
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07901
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16175747
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)739-3900
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6507393939
<b>Email:</b>	DebbieWu@JonesDay.com, WTokmakidis@JonesDay.com
<b>Correspondent Name:</b>	JONES DAY
<b>Address Line 1:</b>	250 VESEY STREET
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10281-1047
<b>ATTORNEY DOCKET NUMBER:</b>	12827-883-999
<b>NAME OF SUBMITTER:</b>	DEBBIE WU
<b>SIGNATURE:</b>	/Debbie Wu/
<b>DATE SIGNED:</b>	03/17/2021
<b>Total Attachments: 13</b>	
source=2017-02-24 Celgene Assignment 2 (NN)#page1.tif source=2017-02-24 Celgene Assignment 2 (NN)#page2.tif source=2017-02-24 Celgene Assignment 2 (NN)#page3.tif source=2017-02-24 Celgene Assignment 2 (NN)#page4.tif source=2017-02-24 Celgene Assignment 2 (NN)#page5.tif source=2017-02-24 Celgene Assignment 2 (NN)#page6.tif	

source=2017-02-24 Celgene Assignment 2 (NN)#page7.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page8.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page9.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page10.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page11.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page12.tif  
source=2017-02-24 Celgene Assignment 2 (NN)#page13.tif

## PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Patent Assignment") is entered into effective as of January 1, 2017, by and between Anthrogenesis Corporation, a New Jersey corporation, d/b/a Celgene Cellular Therapeutics ("Assignor"), and Celgene Corporation, a Delaware corporation ("Assignee").

WHEREAS, Assignor holds right, title, and interest in and to the patents and patent applications listed on the attached Patent Schedule (collectively, the "Patents"); and

WHEREAS, Assignor desires to transfer, set over, convey, assign and deliver to Assignee, and Assignee desires to acquire, all right, title and interest of Assignor in and to the Patents.

NOW, THEREFORE, be it known by all whom it may concern, that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:


1. Assignor agrees to and hereby does assign, transfer and set over to Assignee, its successors and assigns, and Assignee hereby accepts, all of Assignor's entire right, title and interest in and to the Patents, to have and to hold the same, unto Assignee for its own use and enjoyment and for the use and enjoyment of its successors and assigns, for the full term or terms of all such rights, including the right to sue for and collect past damages. The assignment of the Patents shall include the right to file domestic patent applications (including all letters patent, design patents, provisional applications, reissues, divisions, continuations, continuations-in-part, renewals, substitutes, patent disclosures and extensions of any patent or patent application), under the laws of the United States and all other countries that claim the benefit of any of the foregoing applications, and to file foreign patent applications in the name of Assignee or its affiliates, wherever such right may be legally exercised, including the right to claim the benefits of the International Convention for such applications.
2. Assignor hereby authorizes and requests the United States Commissioner of Patents, and the Patent Office officials in foreign countries as are duly authorized by the respective foreign patent laws to issue patents, to issue any and all patents directed to the Patents to Assignee as the owner thereof.
3. From time to time, each of the parties hereto shall execute and deliver all such further assignments or other instruments of conveyance and transfer as the other party may reasonably request for the purpose of giving effect to, or evidencing or giving notice of, the transactions contemplated by this Patent Assignment.
4. This Patent Assignment will be governed by and construed in accordance with the domestic laws of the State of Delaware for contracts entered into and to be performed in such state without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.

5. This Patent Assignment may be executed in counterparts, all of which taken together shall constitute one agreement. For purposes of this Agreement, signatures delivered by facsimile or by email in the portable document format (PDF) or any other electronic format shall be accepted and binding as original signatures.

*[Signature Page Follows]*

IN WITNESS WHEREOF, each of Assignor and Assignee has caused this Patent Assignment to be duly signed on its behalf.

ANTHROGENESIS CORPORATION  
D/B/A CELGENE CELLULAR  
THERAPEUTICS

By:   
Name: Jonathan Biller  
Title: Treasurer & Assistant Secretary

2/24/17  
Date

STATE OF \_\_\_\_\_ )

: ss.

COUNTY OF \_\_\_\_\_ )

The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On \_\_\_\_\_, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.

\_\_\_\_\_  
NOTARY PUBLIC

Residing at \_\_\_\_\_  
\_\_\_\_\_

My Commission Expires: \_\_\_\_\_

CELGENE CORPORATION

By: Mark Allen  
Name: Mark Allen  
Title: CEO

2/27/17  
Date

STATE OF N. J. )

: ss.

COUNTY OF Union

The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On February 27, 2017, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.

FELICIA TURNER  
NOTARY PUBLIC OF NEW JERSEY  
My Commission Expires June 2, 2019

Felicia Turner  
NOTARY PUBLIC

Residing at 86 Morris Ave  
Summit, NJ 07901

My Commission Expires: June 2, 2019

Patent Schedule

CCT FAMIL Y	TITLE	INVENTOR S	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Canada	2,904,014	Feb-06-2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Australia	2013204923	Apr-12-2013	Abandoned	N/A	N/A
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Australia	2014214850	Jul-27-2015	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	New Zealand	711807	Feb-06-2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Japan	2015-557071	Feb-06-2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Hong Kong	16106070.2	Feb-06-2014	Pending	N/A	N/A

CCT FAMIL Y	TITLE	INVENTOR S	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Singapore	1120150702 6W	Feb-06- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	China	2014800200 04.4	Feb-06- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Republic of Korea	2015- 7024323	Feb-06- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	European Patent Office	14749306.8	Feb-06- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	Patent Cooperation Treaty	PCT/US201 4/015113	Feb-06- 2014	Completed	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	United States of America	61/761,548	Feb-06- 2013	Expired	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Liang; Abbott; Liu	United States of America	14/765,896	Feb-06- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY	Abbott; Li; Liang	Canada	2,907,397	Mar-14- 2014	Pending	N/A	N/A



CCT FAMIL Y	TITLE	INVENTOR S	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	Australia	2014240083	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	New Zealand	712373	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	Japan	2016- 502317	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	Hong Kong	16108075.3	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	China	2014800284 01.6	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	European Patent Office	14770151.0	Mar-14- 2014	Pending	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	Patent Cooperation Treaty	PCT/US201 4/027039	Mar-14- 2014	Completed	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	United States of America	61/794,294	Mar-15- 2013	Expired	N/A	N/A
3194	MODIFIED T LYMPHOCYTES	Abbott; Li; Liang	United States of America	14/775,891	Sep-14- 2015	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Canada	2,895,840	Dec-19- 2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Australia	2013204922	Apr-12- 2013	Registered	2013204922	Aug-27- 2015
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Australia	2015210373	Aug-05- 2015	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	New Zealand	709253	Dec-19- 2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Japan	2015- 549689	Dec-19- 2013	Pending	N/A	N/A

CCT FAMIL Y	TITLE	INVENTOR S	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Hong Kong	16103209.3	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Singapore	11201504855W	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	China	201380073452.6	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Israel	239500	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Republic of Korea	2015-7019392	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	European Patent Office	13865885.1	Dec-19-2013	Pending	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	Patent Cooperation Treaty	PCT/US2013/076486	Dec-19-2013	Completed	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	United States of America	61/779,925	Mar-13-2013	Expired	N/A	N/A
3167	CHIMERIC ANTIGEN RECEPTORS	Abbott; Liang; Li	United States of America	14/653,650	Dec-19-2013	Pending	N/A	N/A
3206	METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES	Liang; Liu	Patent Cooperation Treaty	PCT/US2015/039892	Jul-10-2015	Pending	N/A	N/A
3206	METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES	Liang; Liu	United States of America	62/023,618	Jul-11-2014	Expired	N/A	N/A

CCT FAMIL Y	TITLE	INVENTOR S	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3206	METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES	Liang; Liu	United States of America	TBD	Jul-10- 2015		N/A	N/A
3206	METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES	Liang; Liu	Europe	TBD	Jul-10- 2015		N/A	N/A
3206	METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES	Liang; Liu	Japan	TBD	Jul-10- 2015		N/A	N/A
3210	CAR T- LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT	Liang; Liu; Li	Taiwan	104126314	Aug-12- 2015	Pending	N/A	N/A

CCT FAMILLY	TITLE	INVENTORS	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3210	CAR T- LYMPHO CYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT	Liang; Liu; Li	Patent Cooperation Treaty	PCT/US201 5/044611	Aug-11-2015	Published	N/A	N/A
3210	CAR T- LYMPHO CYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT	Liang; Liu; Li	United States of America	62/036,447	Aug-12-2014	Expired	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	Canada	2,916,865	Jun-23-2014	Pending	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	Australia	2014302771	Jun-23-2014	Pending	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	Japan	2016-523826	Jun-23-2014	Pending	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	Hong Kong	16109446.3	Jun-23-2014	Pending	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	European Patent Office	14817301.6	Jun-23-2014	Pending	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	Patent Cooperation Treaty	PCT/US201 4/043609	Jun-23-2014	Completed	N/A	N/A

CCT FAMILY	TITLE	INVENTORS	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	United States of America	61/838,685	Jun-24-2013	Expired	N/A	N/A
3199	METHODS OF EXPANDING T CELLS	Abbott; Foss; Daniel	United States of America	14/900,913	Jun-23-2014	Pending	N/A	N/A
3215	METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS	Zhang; Harris; Jankovic; Kang	United States of America	62/098,547	Dec-31-2014	Expired	N/A	N/A
3215	METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS	Zhang; Harris; Jankovic; Kang	Indonesia	P00201605690	Dec-30-2015	Pending	N/A	N/A

PATENT

REEL: 055630 FRAME: 0539

CCT FAMILY	TITLE	INVENTORS	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3215	METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS	Zhang; Harris; Jankovic; Kang	United States of America	PCT/US2015/068069	Dec-30-2015	Pending	N/A	N/A
3215	METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS	Zhang; Harris; Jankovic; Kang	United States of America	62/139,952	Mar-30-2015	Expired	N/A	N/A
3223	CYTOTOXIC T LYMPHOCYTE PRODUCTION METHODS	Liang; Lu; Liu; Karasiewicz-Mendez; Wiwi; Shah	Argentina	P160104094	Dec-30-2016	Pending	N/A	N/A
3223	CYTOTOXIC T LYMPHOCYTE PRODUCTION METHODS	Liang; Lu; Liu; Karasiewicz-Mendez; Wiwi; Shah	Indonesia	P00201605689	Aug-26-2016	Pending	N/A	N/A
3223	CYTOTOXIC T LYMPHOCYTE PRODUCTION METHODS	Liang; Lu; Liu; Karasiewicz-Mendez; Wiwi; Shah	Taiwan	105144320	Dec-30-2016	Pending	N/A	N/A

CCT FAMILY	TITLE	INVENTORS	COUNTRY	APPL. NO.	FILING DATE	STATUS	PAT. NO.	ISSUE DATE
3223	CYTOTOXIC T LYMPHOCYTE PRODUCTION METHODS	Liang; Lu; Liu; Karasiewicz-Mendez; Wiwi; Shah	Patent Cooperation Treaty	PCT/US2016/069269	Dec-29-2016	Pending	N/A	N/A
3223	CYTOTOXIC T LYMPHOCYTE PRODUCTION METHODS	Liang; Lu; Liu; Karasiewicz-Mendez; Wiwi; Shah	United States of America	62/272,969	Dec-30-2015	Pending	N/A	N/A
3226	METHODS OF TREATING ACUTE MYELOID LEUKEMIA USING NATURAL KILLER CELLS	Fischkoff; Herzberg; Kang; Murphy; Nordberg; Voskarian-Berse; Wilson; Zhang	United States of America	62/333,186	May-07-2016	Pending	N/A	N/A

PATENT

REEL: 055630 FRAME: 0541

RECORDED: 03/17/2021